BioCentury on BioBusiness, Regulation
Table: Fingolimod votes
Back to the parent article
Published on Monday, June 14, 2010
FDA asked its Peripheral and Central Nervous System
Drugs Advisory Committee to vote on nine questions related to the approvability
of fingolimod from Novartis AG (NYSE:NVS; SIX:NOVN) to treat patients
with relapsing-remitting multiple sclerosis (RRMS). Despite evidence of increased
rates of bradycardia at first dose, the development of macular edema and a
gradual decline in pulmonary function in clinical trials of the oral once-daily
sphingosine 1-phosphate (S1P) receptor
68 words displayed of 326 words total.
Get the Full Text...
All contents Copyright © 1993-2012 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Purchase This Article
Learn what you're missing.
Broaden your Knowledge Base
The BioCentury Publications Package provides the essential coverage and analysis required by global biopharma decision makers.
Take advantage of our free trials and discover why BioCentury is the choice of biopharma professionals around the globe.
Free Trials Begin the Week Following Sign-up
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your records.
close [ X ]